Dr. Kim on the Importance of Biomarker Testing for Lung Cancer
Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.
Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.
According to Kim, it is important to gather a patient’s tissue to make an informed decision on the stage of the patient and the treatment options available.
Fifty-percent of patients with non-small cell lung cancer (NSCLC) will have an EGFR, ALK, ROS1, BRAF, or PD-L1 mutation. This determines whether a patient will receive chemotherapy, explains Kim.
